Neofordex

Country: European Union

Language: English

Source: EMA (European Medicines Agency)

Buy It Now

Active ingredient:

dexamethasone

Available from:

THERAVIA

ATC code:

H02AB02

INN (International Name):

dexamethasone

Therapeutic group:

Corticosteroids for systemic use

Therapeutic area:

Multiple Myeloma

Therapeutic indications:

Treatment of multiple myeloma.

Product summary:

Revision: 11

Authorization status:

Authorised

Authorization date:

2016-03-16

Patient Information leaflet

                                23
B. PACKAGE LEAFLET
24
PACKAGE LEAFLET: INFORMATION FOR THE PATIENT
NEOFORDEX 40 MG TABLET
dexamethasone
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE BECAUSE IT CONTAINS IMPORTANT
INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor or pharmacist.
-
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them, even if
their signs of illness are the same as yours.
-
If you get any side effects, talk to your doctor or pharmacist. This
includes any possible side effects
not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
What Neofordex is and what it is used for
2.
What you need to know before you take Neofordex
3.
How to take Neofordex
4.
Possible side effects
5.
How to store Neofordex
6.
Contents of the pack and other information
1.
WHAT NEOFORDEX IS AND WHAT IT IS USED FOR
Neofordex is a medicine that contains the active substance
dexamethasone. Dexamethasone is a type of
hormone called a glucocorticoid, sometimes called a corticoid or
corticosteroid, with various actions
including effects on white blood cells, which form part of the immune
system (the body’s natural defences).
Dexamethasone is similar to glucocorticoids which are naturally
produced in the body.
Neofordex is used to treat adult patients with multiple myeloma, a
cancer of the blood affecting the white
blood cells that produce antibodies. Neofordex will be given in
combination with other medicines for
multiple myeloma. They act together by killing cancerous white blood
cells.
2.
WHAT YOU NEED TO KNOW BEFORE YOU TAKE NEOFORDEX
_ _
DO NOT TAKE NEOFORDEX
−
if you are allergic to dexamethasone or any of the other ingredients
of this medicine (listed in section 6);
−
if you have a viral infection, especially viral hepatitis, herpes,
chickenpox or shingles;
−
if you have an untreated psychiatric illness.
WARNINGS AND PRECAUTIONS
Talk to your doctor, pharmacist, nurse, before taking Neofordex
esp
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
Neofordex 40 mg tablets
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each tablet contains dexamethasone acetate equivalent to 40 mg
dexamethasone.
Excipient with known effect
Each tablet contains 98.1 mg lactose.
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Tablet
White, oblong (11 mm × 5.5 mm) tablet, with “40 mg” engraved on
one side..
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Neofordex is indicated in adults for the treatment of symptomatic
multiple myeloma in combination with
other medicinal products.
_ _
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
Treatment must be initiated and monitored under the supervision of
physicians experienced in the
management of multiple myeloma.
Posology
The dose and administration frequency varies with the therapeutic
protocol and the associated treatment(s).
Neofordex administration should follow instructions for dexamethasone
administration when described in
the Summary of Product Characteristics of the associated treatment(s).
If this is not the case, local or
international treatment protocols and guidelines should be followed.
Prescribing physicians should carefully
evaluate which dose of dexamethasone to use, taking into account the
condition and disease status of the
patient.
The usual posology of dexamethasone is 40 mg once per day of
administration.
At the end of dexamethasone treatment, the dose should be tapered in a
stepwise fashion until a complete
stop.
_Missed dose_
The tablet should be taken immediately if the dose was missed for less
than 12 hours.
The next tablet should be taken at the usual time, if the dose was
missed for more than 12 hours.
In case of a missed dose, a double dose must not be taken.
Special population
_Elderly _
3
In elderly and/or frail patients, where the dose needs to be reduced,
it can be decided to prescribe another
product containing a lower dose of dexamethasone, according to the
appropriate treatment regimen.
_ _
_ _

                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 17-05-2023
Summary of Product characteristics Summary of Product characteristics Bulgarian 17-05-2023
Public Assessment Report Public Assessment Report Bulgarian 01-04-2016
Patient Information leaflet Patient Information leaflet Spanish 17-05-2023
Public Assessment Report Public Assessment Report Spanish 01-04-2016
Patient Information leaflet Patient Information leaflet Czech 17-05-2023
Public Assessment Report Public Assessment Report Czech 01-04-2016
Patient Information leaflet Patient Information leaflet Danish 17-05-2023
Public Assessment Report Public Assessment Report Danish 01-04-2016
Patient Information leaflet Patient Information leaflet German 17-05-2023
Public Assessment Report Public Assessment Report German 01-04-2016
Patient Information leaflet Patient Information leaflet Estonian 17-05-2023
Public Assessment Report Public Assessment Report Estonian 01-04-2016
Patient Information leaflet Patient Information leaflet Greek 17-05-2023
Public Assessment Report Public Assessment Report Greek 01-04-2016
Patient Information leaflet Patient Information leaflet French 17-05-2023
Public Assessment Report Public Assessment Report French 01-04-2016
Patient Information leaflet Patient Information leaflet Italian 17-05-2023
Public Assessment Report Public Assessment Report Italian 01-04-2016
Patient Information leaflet Patient Information leaflet Latvian 17-05-2023
Public Assessment Report Public Assessment Report Latvian 01-04-2016
Patient Information leaflet Patient Information leaflet Lithuanian 17-05-2023
Summary of Product characteristics Summary of Product characteristics Lithuanian 17-05-2023
Public Assessment Report Public Assessment Report Lithuanian 01-04-2016
Patient Information leaflet Patient Information leaflet Hungarian 17-05-2023
Summary of Product characteristics Summary of Product characteristics Hungarian 17-05-2023
Public Assessment Report Public Assessment Report Hungarian 01-04-2016
Patient Information leaflet Patient Information leaflet Maltese 17-05-2023
Public Assessment Report Public Assessment Report Maltese 01-04-2016
Patient Information leaflet Patient Information leaflet Dutch 17-05-2023
Public Assessment Report Public Assessment Report Dutch 01-04-2016
Patient Information leaflet Patient Information leaflet Polish 17-05-2023
Public Assessment Report Public Assessment Report Polish 01-04-2016
Patient Information leaflet Patient Information leaflet Portuguese 17-05-2023
Summary of Product characteristics Summary of Product characteristics Portuguese 17-05-2023
Public Assessment Report Public Assessment Report Portuguese 01-04-2016
Patient Information leaflet Patient Information leaflet Romanian 17-05-2023
Public Assessment Report Public Assessment Report Romanian 01-04-2016
Patient Information leaflet Patient Information leaflet Slovak 17-05-2023
Public Assessment Report Public Assessment Report Slovak 01-04-2016
Patient Information leaflet Patient Information leaflet Slovenian 17-05-2023
Summary of Product characteristics Summary of Product characteristics Slovenian 17-05-2023
Public Assessment Report Public Assessment Report Slovenian 01-04-2016
Patient Information leaflet Patient Information leaflet Finnish 17-05-2023
Public Assessment Report Public Assessment Report Finnish 01-04-2016
Patient Information leaflet Patient Information leaflet Swedish 17-05-2023
Public Assessment Report Public Assessment Report Swedish 01-04-2016
Patient Information leaflet Patient Information leaflet Norwegian 17-05-2023
Summary of Product characteristics Summary of Product characteristics Norwegian 17-05-2023
Patient Information leaflet Patient Information leaflet Icelandic 17-05-2023
Summary of Product characteristics Summary of Product characteristics Icelandic 17-05-2023
Patient Information leaflet Patient Information leaflet Croatian 17-05-2023
Public Assessment Report Public Assessment Report Croatian 01-04-2016

Search alerts related to this product

View documents history